RAPT: RAPT Therapeutics, Inc. Analyst Consensus Forecast
RAPT Therapeutics, Inc. (RAPT) minimizes research risks by developing treatments for cancer and inflammatory processes. The company is currently adjusting its trial plan, focusing on its most reliable assets. The business relies on the selective blocking of CCR4 receptors, which keeps demand stable at a value of 58.12. The available price action chart clearly demonstrates the dynamics of this immune drug developer.
Analytical breakdowns for RAPT Therapeutics (RAPT)
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity RAPT Therapeutics, Inc.|RAPT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital RAPT Therapeutics Inc.|RAPT - Company Aggregate Debts|Debts to Book Capitalization RAPT|RAPT - Company Long-Term Debt|Company Short-Term Loans and Borrowings RAPT Therapeutics|Quick Liquidity Indicator rapt.com
- earnings and valuation multiples indicators:
RAPT - Net Profit|Projected Future Earnings RAPT Therapeutics, Inc.|RAPT - Price to Earnings Ratio|Future Price to Earnings Multiple rapt.com|RAPT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio RAPT|RAPT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months RAPT Therapeutics|RAPT - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months rapt.com|RAPT - Net earnings per share growth this year|Earnings growth forecast for next year RAPT Therapeutics, Inc.
General company analysis:RAPT rapt.com
This metric aggregates the weighted average expert expectations for the asset's fair value, determining the investment's margin of safety through the lens of fundamental valuations. The trend of the weighted consensus target for RAPT Therapeutics, Inc. (RAPT) reflects the capitalization's sensitivity to raw material supply disruption risks and the complexities of international clinical trials, signaling either a business revaluation or stability amid geopolitical instability.
Competitors of RAPT Therapeutics, Inc.
ARGX (argenx.com) - Fair Value Consensus|Analyst Consensus Forecast BNTX (BioNTech)|Analyst Consensus Forecast Abivax SA ABVX|ADMA - Price Target Chart|Forecast Levels Chart PTGX|IMVT (Immunovant, Inc.) - Consensus Target|KNSA: Analyst Forecast Prices|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|ACRS - Price Target Chart|Fair Value Consensus KYTX (Kyverna Therapeutics, Inc)|TLSA: Analyst Consensus Forecast|cabalettabio.com (CABA) - Analyst Consensus Forecast|Price Target Chart Ventyx Biosciences, Inc.|Theratechnologies, Inc. - Forecast Levels Chart|Consensus Target AVTX (Avalo Therapeutics Inc.)|Analyst Forecast Prices ELDN|Agenus - Consensus Target|Fair Value Consensus CLYM|ZURA: Consensus Target|aTyr Pharma Inc - Analyst Forecast Prices|ADAG: Analyst Consensus Forecast|Ikena Oncology - Fair Value Consensus|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Average Forecast Price Equillium Bio EQ|Price Target Chart Connect Biopharma (CNTB)|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast ATRA (Atara Bio)|Analyst Consensus Forecast InflaRx NV IFRX|XFOR - Price Target Chart|Forecast Levels Chart ACET|CELU: Analyst Consensus Forecast|Average Forecast Price INmune Bio Inc (INMB)|Consensus Target BRNS|Analyst Consensus Forecast Kezar Life Sciences Inc|Consensus Target SABS (SAB Biotherapeutics)|Analyst Forecast Prices AKTX|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Analyst Median Target Q32 Bio Inc (QTTB)|GeoVax Labs Inc - Analyst Consensus Forecast|Edesa Biotech Corp (EDSA) - Consensus Target|iBio, Inc. (IBIO) - Price Target Chart|CARM - Analyst Median Target|Consensus Target XTLB|BOLT: Fair Value Consensus|Analyst Consensus Forecast HCWB|Analyst Median Target aptevotherapeutics.com|Price Target Chart AIM ImmunoTech AIM|ADTX: Broker Consensus Forecast|GRI Bio - Analyst Consensus Forecast|XORTX Therapeutics Inc (XRTX) - Consensus Target|HIND (ReShape Lifesciences) - Consensus Target|REVB - Analyst Median Target|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Analyst Consensus Forecast CALI|Analyst Consensus Forecast affimed.com (AFMD)|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGMS: Consensus Target|iteostherapeutics.com - Analyst Forecast Prices|Ocean Biomedical (OCEA) - Price Target Chart|Forecast Levels Chart TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
